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responsibility of XAbstract A reliable, selective and sensitive liquid chromatography tandem mass spectrometry method
was developed and validated for the quantiﬁcation of lamotrigine in human plasma using lamotri-
gine-13C3, d3 as an internal standard. Analyte and internal standard were extracted from human plasma
by solid-phase extraction and detected in positive ion mode by tandem mass spectrometry with
electrospray ionization (ESI) interface. Chromatographic separation was performed on a Chromoliths
SpeedROD; RP-18e column (504.6 mm i.d.) using acetonitrile: 570.1 mM ammonium formate solution
(90:10, v/v) as the mobile phase at a ﬂow rate of 0.500 mL/min. The calibration curves were linear over the
range of 5.02–1226.47 ng/mL with the lower limit of quantitation validated at 5.02 ng/mL. The analytes
were found stable in human plasma through three freeze (20 1C)-thaw (ice-cold water bath) cycles and
under storage on bench-top in ice-cold water bath for at least 6.8 h, and also in the mobile phase at 10 1C
for at least 57 h. The method has shown good reproducibility, as the intra- and inter-day precisions were
within 3.0%, while the accuracies were within 76.0% of nominal values. The validated LC–MS/MS
method was applied for the evaluation of pharmacokinetic and bioequivalence parameters of lamotrigine
after an oral administration of 50 mg lamotrigine tablet to thirty-two healthy adult male volunteers.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting by E
.001
4768130;
baxy.com (P. Partani)
i’an Jiaotong University.1. Introduction
Lamotrigine[3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine;
(Fig. 1)], a phenyl-traizine derivative, an effective antiepileptic
agent, has been used widely in the treatment of epilepsy and
bipolar disorders [1]. It exhibits excellent oral bioavailability
with ﬁrst-order linear pharmacokinetics and has a mean plasmalsevier B.V. All rights reserved.
Fig. 1 Chemical structure of lamotrigine and lamotrigine-13C3, d3.
S. Ghatol et al.76half-life of approximately 24 h. Lamotrigine is a lipophilic weak
base with plasma protein binding of 55%. It gets extensively
metabolized in human liver via hepatic glucuronidation by
uridine 50-diphosphate-glucuronosyl transferase (UGT1A4) [2].
Over the years, a variety of analytical methods were
reported for the determination of lamotrigine in biological
samples. These include radioimmunoassay [3], high perfor-
mance liquid chromatography (HPLC) methods with ultra-
violet detection [4–21], capillary electrophoresis [22], gas
chromatography–mass spectrometry (GC–MS) [23], electro-
spray ionization–mass spectrometry (ESI–MS) [24,25]. These
conventional quantitative HPLC methods with classical ultra-
violet or capillary electrophoresis detection provide insufﬁ-
cient sensitivity, longer chromatographic run time and a labor
intensive work-up procedure which nowadays are less favored
in industries to support clinical studies.
Among the currently available bio-analytical techniques,
liquid chromatography coupled with tandem mass spectro-
metry (LC–MS/MS) has been emerged as the preeminent
analytical tool for quantiﬁcation of small molecular weight
drugs in biological matrix. Very few methods employing LC–
MS/MS have been published for the determination of lamo-
trigine in human plasma [26–28]. Shah et al. [27] reported a
methodology that has limit of quantiﬁcation of 25 ng/mL
achieved while utilizing multiplexing technique. More recently,
Hotha et al. [28] reported a method for quantiﬁcation of
lamotrigine in human plasma using liquid–liquid extraction
technique.
The main objective of this study was to develop a fast,
sensitive and robust method to quantify lamotrigine using
isotopically labeled internal standard (ISTD), in order to
extend its application to assess the bioequivalence of two
lamotrigine 50 mg tablet formulations in healthy volunteers.2. Experimental
2.1. Chemicals and materials
Working standards of lamotrigine (99.0%) and lamotri-
gine-13C3, d3 (99.2%) for use as an internal standard (ISTD)
were procured from Vivan Life Sciences, India and TLC
Pharma Chem., Canada, respectively. Ammonium formate of
LC–MS grade was obtained from FLUKA (Sigma-Aldrich,
Steinheim, USA). Acetonitrile and methanol of HPLC grade
were obtained from Spectrochem (Mumbai, India) and Fisher
Scientiﬁc (Mumbai, India), respectively. Cleanert PEP-H,
30 mg/mL, solid phase cartridges were obtained from Agela
technologies (Tianjin, China). All aqueous solutions and
buffers were prepared using water that was puriﬁed using
Milli-Qs Gradient A10s (Millipore, Moscheim Cedex,France). Different individual lots of K3EDTA (ethylene
diamine tetra acetic acid tri potassium salt) human plasma,
which were used to prepare calibration standards and quality
control (QC) samples, were obtained from Yash Laboratories
(Mumbai, India).
2.2. Preparation of stock solution, standard and quality
control samples
Stock solutions of lamotrigine and lamotrigine-13C3, d3
(1000 mg/mL) were prepared in methanol, stored in refrigera-
tor between 1 and 10 1C, and protected from light until use.
Working solutions of lamotrigine (ranging from 0.25 to
61.32 mg/mL) were prepared by serial dilution of the stock
solution in methanol–water (50:50, v/v). A 200 mL aliquot of
each working solution was added to pooled blank K3EDTA
plasma to yield spiked calibration standards at eight different
concentrations ranging from 5.02 to 1226.47 ng/mL. Simulta-
neously quality control (QC) samples for determination of
accuracy and precision in K3EDTA plasma at four concentra-
tions (5.03, 12.52, 391.28 and 978.20 ng/mL) were prepared in
the similar manner as that of calibration standards. Calibra-
tion curve plasma standards and quality control samples were
stored at around 20 1C until assayed or used for validating
the analytical method. The amount of stock solution in all
spiked samples was kept at 2% of the total sample volume to
minimize any systemic errors between the real samples and
spiked samples.
The ISTD working solution (500.00 ng/mL) for routine use
was prepared by diluting the lamotrigine-13C3, d3 stock
solution in methanol–water (50:50, v/v).
2.3. Sample preparation
Plasma samples stored at around 20 1C were thawed on the
day of extraction at room temperature followed by vortexing
to ensure homogeneity. An eppendorf pipette was used to
aliquot 0.300 mL of spiked plasma samples into polypropylene
tubes (13 mm 50 mm). To each tube then added 0.050 mL of
internal standard working solution (500.00 ng/mL, lamotri-
gine-13C3, d3 in methanol–water, 50:50, v/v) with the use of
multistepper and vortexed approximately for 30 s. To these
tubes 0.400 mL of water was then added, and vortexed again
approximately for 30 s. The total sample was then loaded
using an eppendorf pipette on SPE cartridge and centrifuged
at 1500 rpm for 1 min. Before that the Cleanert PEP-H
cartridge was conditioned with 0.500 mL of methanol fol-
lowed by 0.500 mL of water. After loading of the samples, the
cartridge was washed once with 1 mL of 20% methanol–water
mixture followed by 1 mL of water. Finally, the analyte and
ISTD were eluted with 1 mL of methanol. The extracted
LC–MS/MS estimation of lamotrigine 77samples were evaporated to dryness using a Zymark Turbo-
Vap LV evaporator (Caliper, Hopkinton, MA, USA) and
reconstituted with 0.400 mL of the mobile phase. Using an
eppendorf pipette the reconstituted samples were transferred
to autosampler vials. 10 mL was injected into the LC–MS/MS
system for analysis.2.4. LC/ESI-MS/MS instrumentation and analytical
conditions
The liquid chromatography separation was performed using a
Shimadzu scientiﬁc instruments (Shimadzu Corporation; Kyoto,
Japan) consisted of two LC-20AD delivery pumps, an on-line
DGU-20A3 prominence solvent degasser, an SIL-HTc Shimadzu
autosampler and a CBM-20A prominence column oven. Liquid
chromatographic separations were achieved using Chromoliths
SpeedROD; RP-18e column (504.6 mm) (Merck Scientiﬁc,
USA). An injection volume of 10 mL was used for each analysis.
Mobile phase consisted of acetonitrile: 570.1 mM ammonium
formate solution (90:10, v/v). The ﬂow rate of the mobile phase
was set at 0.500 mL/min. The column and autosampler were
maintained at 3571 1C and 1071 1C, respectively.
Samples were analyzed with an API-3000 triple quadrupole
mass spectrometer (MDS Sciexs; Toronto, Canada) equipped
with an electrospray ionization source operating in positive
ion mode. Nitrogen was used as the nebulizer, auxillary,
collision and curtain gas. Analytes were detected by tandem
mass spectrometry using multiple reaction monitoring (MRM)
of precursor-product ion transitions with 200 ms dwell time, at
m/z 256.1/211.3 for lamotrigine and m/z 262.1/217.2 for
lamotrigine-13C3, d3.
The instrument response was optimized by syringe pump
infusion of lamotrigine and lamotrigine-13C3, d3 in the mobile
phase by constant ﬂow (10 mL/min) into the stream of the
mobile phase eluting from the LC column. The main working
source/gas parameters of the mass spectrometer were opti-
mized and maintained as follow: collision activated dissocia-
tion (CAD) gas, 10; curtain gas, 8; nebulizer gas, 12; turbo ion
spray (IS) voltage, 2000 V; source temperature, 450 1C. The
compound parameters like, declustering potential (DP),
entrance potential (EP), focusing potential (FP), collision
energy (CE), and collision cell exit potential (CXP) were
optimized and set at 48, 10, 150, 37 and 14 V respectively,
for lamotrigine and lamotrigine-13C3, d3.
Calibration curves were constructed by calculating the
analyte to ISTD peak area ratio (y) against analyte concen-
trations (x). Data acquisition and processing were performed
using Analyst version 1.4.1 software (MDS Sciexs; Toronto,
Canada).2.5. Method validation
A full method validation was performed according to guide-
lines set by the USFDA [29]. The validation of this procedure
was performed in order to evaluate the method in terms of
selectivity, sensitivity, linearity of response, accuracy, preci-
sion, recovery, matrix effect, and stability of analyte during
both short-term sample processing and long-term storage.2.5.1. Selectivity
The selectivity of the method towards endogenous plasma
matrix components and concomitant medications was assessed
in eight lots of blank human plasma (six K3EDTA, one
lipemic and one haemolysed). They were processed and
analyzed using the proposed extraction protocol and the set
chromatographic conditions for lamotrigine at the lower limit
of quantitation (LLOQ) level.2.5.2. Linearity and LLOQ
The linearity of the method was determined by analysis of
standard plots associated with an eight point standard
calibration curve. Calibration curves from accepted three
precision and accuracy batches were used to establish linearity.
Peak area ratios of analyte/ISTD obtained from MRM were
utilized for the construction of calibration curves; using
weighted (1/x2) linear least squares regression of the plasma
concentrations and the measured peak area ratios. Back-
calculations were made from these curves to determine the
concentration of lamotrigine in each calibration standards and
the resulting calculated parameters were used to determine
concentrations of analyte in quality control or unknown
samples. The correlation coefﬁcient r40.98 was desirable for
all the calibration curves. The lowest standard on the calibra-
tion curve was to be accepted as the LLOQ, if the analyte
response was at least ﬁve times more than that of drug free
(blank) extracted plasma. In addition, the analyte peak of
LLOQ sample should be identiﬁable, discrete, and reproduci-
ble with accuracy within 720.0% and a precision r20.0%.
The deviation of standards other than LLOQ from the
nominal concentration should not be more than 715.0%.2.5.3. Accuracy and precision
Intra- and inter-day accuracies were expressed as a percentage
of deviation from the respective nominal value and the
precision of the assay was measured by the percent coefﬁcient
of variation (%CV) at concentrations. Intra-day precision and
accuracy were assessed by analyzing six replicates of the
quality control samples at four levels during a single analytical
run. The inter-day precision and accuracy were assessed by
analyzing 18 replicates of the quality control samples at each
level through three precision and accuracy batches runs on
2 consecutive validation days. The deviation at each concen-
tration level from the nominal concentration was expected to
be within 715.0% except lower limit of quality control
(LLOQC), for which it should not be more than 20.0%.
Similarly, the mean accuracy should not deviate by 715.0%
except for the LLOQC where it can be 720.0% of the
nominal concentration.2.5.4. Recovery
The relative extraction recoveries for the analyte and ISTD at
low, middle and high QC concentration levels were determined
by measuring the mean peak area response of six replicates of
extracted quality control samples against the mean peak area
response of six replicates each of three neat solutions contain-
ing analyte and a neat solution containing ISTD at concen-
trations equivalent to those obtained in the ﬁnal extracted
concentration for the analyte and ISTD in the quality control
samples.
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Matrix effect was assayed at two concentration levels
(LLOQC and HQC). Six different blank plasma lots (4
normal, 1 haemolysed, 1 lipemic), free of any signiﬁcant
interference at the RT of analyte and ISTD, were selected
and spiked with the working solutions of LLOQC and HQC.
Spiked samples from each plasma lot were processed in
duplicate and quantitated against freshly spiked calibration
curve. The matrix effect is validated to be nulliﬁed if the
accuracy and precision do not deviate by 715.0% for HQC
and 720.0% for LLOQC of the nominal concentration.
The matrix factor is deﬁned as the peak area response in the
presence of matrix ions versus the peak area response in the
absence of matrix ions. Since this method involved terminal
drying step, biological matrix samples were prepared by
reconstituting the post-extracted blank plasma samples with
three neat solutions containing lamotrigine and lamotrigi-
ne-13C3, d3 at concentration representing the ﬁnal extracted
concentration for the analyte (low, medium and high quality
control concentration) and ISTD. The control samples were
the same neat solutions prepared in the mobile phase. Matrix
factor was evaluated using six different blank plasma lots (4
normal, 1 haemolysed, 1 lipemic) and determined by measur-
ing the respective mean peak area response and mean analyte/
ISTD peak area ratio (ISTD normalized MF) of biological
matrix sample against the mean peak area response and mean
analyte/ISTD peak area ratio of neat solutions.
2.5.6. Stability
The absolute stability of lamotrigine in plasma was assessed by
analyzing four replicates of QC samples at low and high
concentrations of 12.52 and 978.20 ng/mL during the sample
storage and processing procedures. Bench-top stability was
assessed in ice cold water bath for 7 h, which exceeds the
residence time of the sample processing procedures. The
freeze-thaw stability was evaluated after undergoing three
freeze (at around 20 1C)-thaw (ice cold water bath) cycles.
Long-term stability was assessed after storage of the test
samples at around 20 1C for 48 days. The autosampler
storage stability was determined by storing the reconstituted
QC samples for 57 h under autosampler condition (main-
tained at 10 1C) before being analyzed. All stability exercises
were performed against freshly spiked calibration standards
processed along with freshly spiked four replicates of QC
samples at low and high concentrations which act as compar-
ison samples for determining the percentage absolute stability
of lamotrigine during the sample storage and processing
procedures. The analyte was considered stable in plasma at
each concentration if the mean calculated concentration of
stability samples does not deviate by 715.0% of the mean
calculated concentration of comparison quality control
samples.
The working solutions and stock solutions of lamotrigine
and ISTD were also evaluated for their stability at room
temperature for 9 h and at refrigerator temperature (between 1
and 10 1C) for 23 days, respectively.
2.6. Method application
An open label, balanced, randomized, two-treatment, two-
period, two-sequence, single-dose, crossover design was usedfor the assessment of pharmacokinetics and bioequivalence.
Thirty-two healthy adult male volunteers who gave written
informed consent took part in this study. The study was
approved by Ethics Committee of Institutional Review Board
at Majeedia Hospital (New Delhi, India). After an overnight
fast of at least 10 h, all subjects were given a single oral dose of
lamotrigine extended release 50 mg tablet of Ranbaxy and
Lamictals XR
TM
extended release tablets 50 mg (containing
lamotrigine 50 mg) of GlaxoSmithKline during each period of
the study. Blood samples were collected before and at 2, 4, 6,
8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 33, 36, 48, 72, 96,
120, 144 and 168 h post-dose in each period. The plasma was
immediately separated by centrifugation and stored frozen at
around 20 1C until analysis.3. Results and discussion
3.1. Optimization of the mass spectrometric condition
Lamotrigine has amino functionality in its chemical structure;
certainly the mass spectrometric detection in positive ion mode
was evaluated using both electrospray ionization (ESI) as well
as atmospheric pressure chemical ionization (APCI). The
signal intensity obtained in the positive mode with ESI
interface is much higher than that of APCI. The Q1 ESI
spectra were dominated by the protonated quasimolecular ion
[MþH]þ at m/z 256.1 for lamotrigine and 262.1 for lamotri-
gine-13C3, d3 with no other additive and fragments ions were
present (data not shown). The Q1 mass spectra of lamotrigine
shows the isotopic mass distribution pattern upto [Mþ5H]þ
due to the presence of two chlorine atoms. This might lead to
an interference with the transition of isotopic labeled internal
standard with labeling less than four or equivalent; in view of
that we have selected lamotrigine-13C, d3 as an internal
standard. Fig. 2 shows the product ion spectra of lamotrigine
and lamotrigine-13C3, d3. The MS/MS parameters, including
the declustering potential (DP), focusing potential (FP),
collision cell exit potential (CXP), gases (NEB, CAD) and
collision energy (CE), were optimized to identify the most
stable and intense product ion for the analyte and ISTD. The
product ions at m/z 211.3 for lamotrigine and at m/z 217.2 for
lamotrigine-13C3, d3, corresponding to the cleavage of triazine
moiety of the molecule, were observed with higher abundance
and greater stability.
During the method development different additives of
varying strength were added to the mobile phase, so as to
obtain higher abundance of protonated parent ion of analyte
and ISTD. Use of ammonium formate solution of strength
570.1 mM in the mobile phase enhances the occurrence of
[MþH]þ and eventually results in an improvement in area
response for both the analyte and ISTD.
3.2. Optimization of chromatographic condition
A number of reversed-phase columns, such as Ascentis-C18,
Hypersil-C18, Zorbax SB-CN, Chromoliths SpeedROD and
Phenomenex Luna, were tested to obtain optimal selectivity,
efﬁciency, suitable retention time and symmetric peak shape
for the analyte and ISTD. In industrial research cutting of
the separation time is always in focus in order to attain the
high throughput. The Chromoliths SpeedROD column
Fig. 2 The product ion spectra of lamotrigine (A) and lamotrigine-13C3, d3 (B).
LC–MS/MS estimation of lamotrigine 79(504.6 mm i.d.) was selected since it provided good peak shape
and better sensitivity with greater signal to noise (S/N) ratio. The
chromolith columns are composed of porous silica rods with
2 mm micropores, which facilitates fast mass transfers and
results in minimizing the total analytical run time to o3.0 min.
The mobile phase consisting of 570.1 mM ammonium formate
and acetonitrile gave higher signal intensity. Acetonitrile was
chosen as organic phase over methanol as it revealed a higher
mass spectrometric response and with minimal background noise.
Change in percentage of acetonitrile in the mobile phase was
found to have profound inﬂuence on retention time and peak
shape. Thus a mobile phase consisting of acetonitrile: 570.1 mM
ammonium formate solution (90:10, v/v) was used in the
experiment. Under these conditions, lamotrigine and lamotrigi-
ne-13C3, d3 elute at retention time of approximately 1.50 min as
shown in Fig. 3.3.3. Sample preparation optimization
Sample clean-up was focused on solid phase extraction since
this technique mostly provides the cleanest sample compared
to protein precipitation or liquid–liquid extraction. In a
previous study Waters Oasis HLB cartridges were successfully
used to extract analyte from human plasma with absolute
recovery of more than 95% [27]. During initial stages of the
method development, three reversed-phase type solid phase
polymeric supports (Waters Oasis HLB; Agilents Bond Elut
Plexa; and Agelas Cleanert PEP-H) were tested for the
extraction of analyte and ISTD from human plasma. All the
three polymeric supports nearly produced comparable results.
In this work we have utilized Cleanert PEP-H cartridges for
isolation of analyte and ISTD from the plasma samples with
minor modiﬁcation from the previously reported method.
Furthermore, the use of a stable isotopically labeled internal
standard compensated for any possible matrix effect andimproved robustness of this method over the previously
reported work. The extraction procedure described here offers
a rapid way to isolate analyte as well as ISTD from plasma
matrix.3.4. Method validation
3.4.1. Selectivity
Selectivity is the ability of an analytical method to differentiate
and quantify the analyte in the presence of other components
in the sample. Selectivity was ascertained in different batches
of human plasma by comparing the chromatograms of blank
plasma samples with the corresponding spiked LLOQ plasma
samples. Fig. 3 shows the typical chromatograms of a double
blank, blank spiked with ISTD, a spiked plasma sample with
lamotrigine at LLOQ and upper limit of quantitation (ULOQ)
level. As can be seen no interference peak from endogenous
compounds was observed at the retention time of the analyte
and ISTD.3.4.2. Linearity and sensitivity
The method was validated using the above criteria and found
that plasma calibration standard curve containing lamotrigine
was linear over the concentration range of 5.02–1226.47 ng/mL.
The intercept with the y-axis was not signiﬁcantly different from
zero. A typical regression equation was y¼0.0359xþ0.0331 with
a correlation coefﬁcient (r) of 0.9987, where y represents the peak
area ratio of lamotrigine to that of ISTD and x represents the
plasma concentration of lamotrigine.
Although the method was only validated to 5.02 ng/mL, to
match clinical sensitivity requirements, at which the obtained
values were within 76.0% of the spiked values and the intra-
and inter-day coefﬁcients of variation were o3.0% (Table 1).
The lower limit of detection (based on a signal:noise ratio,
S/N¼3) was less than 0.1 ng/mL. Preliminary evaluations
Table 1 Accuracy and precision of the method for the estimation of lamotrigine in human plasma.
Nominal concentration
(ng/mL)
Intra-day (n¼6) Inter-day (n¼18)
Average7SD (ng/mL) Accuracy (%) CV (%) Average7SD (ng/mL) Accuracy (%) CV (%)
5.03 4.7770.08 94.9 1.6 4.8370.11 96.1 2.4
12.52 12.6470.09 100.9 0.7 12.7170.17 101.5 1.3
391.28 388.2672.71 99.2 0.7 388.8173.47 99.4 0.9
978.20 937.73710.64 95.9 1.1 942.4479.60 96.3 1.0
Fig. 3 Representative chromatograms in human plasma: (A) double plasma blank; (B) plasma blank with ISTD; (C) LLOQ, 5.02 ng/mL;
and (D) ULOQ 1226.47 ng/mL. Lamotrigine (left panels, A–D) and its ISTD–lamotrigine-13C3, d3 (right panels, A–D).
S. Ghatol et al.80showed that an LLOQ (S/N¼10) of less than 0.2 ng/mL could
easily be achieved. Nevertheless, LLOQ of 5.02 ng/mL was
chosen in order to estimate lamotrigine in plasma samples
until 168 h.3.4.3. Precision and accuracy
Precision and accuracy of the method were determined by
analyzing quality control samples at four concentrations
within the calibration curve range to validate reproducibility.
Table 1 summarizes the inter- and intra-day precision and
accuracy values for quality control samples. The CV values of
both intra- and inter-day results were below 1.6% and 2.4%,
respectively. Intra- and inter-day accuracies were less than
76.0% at all analyte concentrations. These results above
indicate that the present method has good accuracy, precision
and reproducibility.3.4.4. Recovery
At three QC concentration levels 12.52, 391.28 and 978.20 ng/
mL the relative extraction recovery (mean7SD) for lamotrigine
was 73.274.5%, 78.079.5% and 80.271.0%, respectively. The
mean recovery for the internal standard lamotrigine-13C3, d3 at
the concentration employed was 65.177.7%. The result indicates
that the extraction efﬁciency for lamotrigine using solid phase
extraction was satisfactory, consistent and was not concentration
dependent.
3.4.5. Matrix effect and matrix factor
Matrix effect, ion suppression or enhancement, due to the co-
eluting endogenous component of sample matrix along with the
analyte or internal standard may affect the chromatography and
accuracy of analytical method when developing LC–MS/MS
assay. So, to ensure the selectivity of method, matrix effect as
well as matrix factor on the presented method was evaluated
LC–MS/MS estimation of lamotrigine 81following the procedures described above. Results of the exercise
are summarized in Table 2. Results obtained therein indicate that
no additional variations in plasma concentration due to the use
of different plasma lots were observed. Hence the concentration
of the analyte obtained from clinical study samples should
therefore be considered as reliable.
The matrix ionization suppression or enhancement of the
analyte and ISTD was assessed by measuring the matrix factorTable 2 Matrix effect and matrix factor for lamotrigine in six d
Lots of
human
plasma
Matrix effect Matrix factor
LOQQC
(ng/mL)
HQC
(ng/mL)
LQC M
5.03a 978.20a Using peak
area
response
Using analyte/
ISTD peak area
ratio
U
a
r
Matrix
Lot# 1
4.77 956.64 0.87 1.00 0
4.75 939.95
Matrix
Lot# 2
4.74 942.31 0.84 1.00 0
4.69 943.95
Matrix
Lot# 3
4.64 956.85 0.86 1.01 0
4.84 944.23
Matrix
Lot# 5
4.66 932.22 0.81 1.00 0
4.79 944.49
Matrix
Lot# 5b
4.69 945.21 0.77 1.00 0
4.80 950.09
Matrix
Lot# 6c
4.77 939.93 0.79 1.00 0
4.77 941.23
Average 4.74 944.76 0.82 1.00 0
SD (7) 0.061 7.001 0.040 0.004 0
CV(%) 1.3 0.7 4.8 0.4 3
Accuracy
(%)
94.3 96.6
aNominal concentration (ng/mL).
bHemolyzed plasma lot.
cLipemic plasma lot.
Table 3 Stability data for lamotrigine in human plasma under v
Stability Sample Nominal
concentrati
Freeze/thaw stability (three freeze/thaw
cycles at 20 1C)
Comparison
samples
12.51
977.38
Stability
samples
12.52
978.20
Bench top stability (6.8 h in ice-cold
water bath)
Comparison
samples
12.51
977.38
Stability
samples
12.52
978.20
In-injector stability (57 h) Comparison
samples
12.51
977.38
Stability
samples
12.52
978.20
Long-term stability (48 days) Comparison
samples
12.55
980.84
Stability
samples
12.52
978.20
% Absolute stability¼(average concentration of stability samples/aver
Full name of C.F.¼concentration of stability sample/concentration of
N/AP: Not Applicableat three QC concentration levels. The mean absolute matrix
factor at the low, medium and high QC concentrations from
six lots of plasma samples was 0.82, 0.86, and 0.85, respec-
tively (Table 2). The CVs of absolute matrix factor and ISTD
normalized matrix factor from six lots of plasma samples were
o2.4%. These results showed that ion suppression or
enhancement from the plasma matrix was negligible under
the current conditions.ifferent lots of human plasma.
QC HQC
sing peak
rea
esponse
Using analyte/
ISTD peak area
ratio
Using peak
area
response
Using analyte/
ISTD peak area
ratio
.88 1.00 0.83 1.00
.90 1.00 0.84 1.00
.83 1.00 0.87 1.00
.85 1.00 0.81 1.00
.88 0.99 0.87 0.99
.84 1.00 0.86 1.00
.86 1.00 0.85 1.00
.027 0.004 0.024 0.004
.2 0.4 2.9 0.4
arious conditions (n¼4).
on (ng/mL)
Average7SD Accuracy
(%)
CV
(%)
Absolute
stability (%)
12.8870.15 102.9 1.1 N/AP
960.9478.64 98.3 0.9 N/AP
12.9370.08 103.3 0.6 100.4
951.5475.99 97.3 0.6 98.9
12.7070.23 101.5 1.8 N/AP
924.97737.03 94.6 4.0 N/AP
12.8470.33 102.6 2.5 101.1
945.88712.97 96.7 1.4 102.2
12.4370.21 99.4 1.7 N/AP
1006.39730.76 103.0 3.1 N/AP
12.5570.09 100.2 0.7 100.8
1016.19729.73 103.9 2.9 100.9
12.7270.14 101.4 1.1 N/AP
957.7777.19 97.6 0.8 N/AP
12.6170.08 100.7 0.7 99.4
939.63711.87 96.1 1.3 98.4
age concentration of comparison samplesC.F.) 100.
comparison sample.
Fig. 4 The linear mean plasma concentration versus time proﬁle of lamotrigine in plasma.
R stands for reference formulation, T stands for test formulation.
Table 4 Pharmacokinetic parameters (mean7SD) of
lamotrigine, after the administration of an oral dose of
50 mg test or reference formulations to healthy Indian male
volunteers.
Parameters Reference Test
tmax (h) 19.876.3 18.576.2
cmax (ng/mL) 4777141 4837128
AUC0-t (mg h/mL) 29.2712.6 28.3710.4
t1/2 (h) 34.778.8 34.379.2
S. Ghatol et al.823.4.6. Stability studies
The absolute stability of lamotrigine was investigated at two
concentration levels of QC samples (low and high) to cover
expected conditions during analysis, storage and processing of
all samples, which include the stability data from various
stability exercise like in-injector, bench-top, freeze/thaw and
long-term stability tests. The stability results summarized in
Table 3 showed that lamotrigine spiked into human plasma
was stable for at least 6.8 h in ice-cold water bath, for at least
57 h in the mobile phase at 10 1C under autosampler storage
condition, for 48 days at around 20 1C and during three
freeze-thaw cycles. The stock solutions of lamotrigine and
ISTD were found stable at refrigerator temperature (between 1
and 10 1C) for 23 days and the working solutions of lamo-
trigine and ISTD were found stable for about 9 h at room
temperature.3.4.7. Method application
This developed method was applied to a pharmacokinetic
study of lamotrigine in 32 healthy adult male volunteers
following oral administration of 50 mg of lamotrigine tablet.
The mean concentration–time proﬁle of lamotrigine in these
volunteers is shown in Fig. 4 and the mean estimated
pharmacokinetic parameters derived from the plasma concen-
tration proﬁles are summarized in Table 4.4. Conclusions
A rapid, sensitive and selective LC–MS/MS method for the
quantitation of lamotrigine in human plasma was developed and
validated. The assay was linear from 5.02 to 1226.47 ng/mL. The
lowest standard generated typical signal to noise ratios around
200. Solid phase extraction methodology was adopted in plasma
sample preparation, which provides consistent extraction recov-
ery with minimal endogenous interference and matrix effect.
Lamotrigine was found stable during storage, processing, and
analysis in human plasma samples. The results indicate the
method to be sensitive, selective, accurate and reproducible. The
applicability of the method was demonstrated in a bioequiva-
lence study of lamotrigine in healthy male volunteers.
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